ArticleThe Journal of experimental medicine2008
Inciting inflammation: the RAGE about tumor promotion.
Article in The Journal of experimental medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Immune status of patients with inherited bone marrow failure syndromes.American journal of hematology · 2015Trial
- Chronic Trichuris muris infection causes neoplastic change in the intestine and exacerbates tumour formation in APC min/+ mice.PLoS neglected tropical diseases · 2017Article
- Effect of IL-17 in the development of colon cancer in mice.Oncology letters · 2016Article
- Overexpression of soluble RAGE in mesenchymal stem cells enhances their immunoregulatory potential for cellular therapy in autoimmune arthritis.Scientific reports · 2016Article
- Choline and Cystine Deficient Diets in Animal Models with Hepatocellular Injury: Evaluation of Oxidative Stress and Expression of RAGE, TNF-α, and IL-1β.Oxidative medicine and cellular longevity · 2015Article
- Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.PloS one · 2014Article
- Article
- Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity.Cell reports · 2012Article
- Low concentration of S100A8/9 promotes angiogenesis-related activity of vascular endothelial cells: bridges among inflammation, angiogenesis, and tumorigenesis?Mediators of inflammation · 2012Article
- IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors.Cancer cell international · 2011Article
- Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review.ISRN veterinary science · 2011Article
- The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker.Journal of translational medicine · 2010Article
- The biologic importance of tumor-infiltrating lymphocytes.Journal of cutaneous pathology · 2010Article
- Proteomic analyses of pancreatic cyst fluids.Pancreas · 2009Article
- alpha(5)beta(1) Integrin Ligand PHSRN Induces Invasion and alpha(5) mRNA in Endothelial Cells to Stimulate Angiogenesis.Translational oncology · 2009Article
- Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis.British journal of cancer · 2008Article
- Can essential fatty acids reduce the burden of disease(s)?Lipids in health and disease · 2008Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanisms of innate and adaptive immunity play a pivotal role in the development of cancer. Chronic inflammation can drive tumor development, but antitumor immunity can also restrict or even prevent tumor growth. New data show that feed-forward signals downstream of the receptor for advanced glycation end-products (RAGE) can fuel chronic inflammation, creating a microenvironment that is ideal for tumor formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.